CClinicalTrials.gg
CompletedNCT06159647Updated Feb 13, 2024

Consumer Responses to Alcohol Warnings

An interventional study of Mouth cancer warning and Throat cancer warning in Alcohol Drinking, sponsored by Stanford University. Completed at 1 site in United States. Open to participants aged 21 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-13.

Sponsored by Stanford University · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
2,522
Allocation
Not applicable
Ages
21 Years and older
Sex
All
01

Study summary

The primary objective is to evaluate whether alcohol warnings about different topics elicit higher perceived message effectiveness than control messages. The secondary objective is to evaluate whether alcohol warnings about different topics elicit higher reactance than control messages.

Read the detailed description

Participants will complete a within-subjects online randomized experiment in which they will view and rate messages on the risk of alcohol consumption. Participants will view and rate 12 messages total: 10 warning messages and 2 control messages. They will rate each message on perceived message effectiveness (primary outcome) and message reactance (secondary outcome). The 10 warning messages will be about 5 different warning topics (i.e., 2 messages per topic) and the 2 control messages will be about 1 control topic (2 messages per topic). In this within-subjects experiment, the survey will present the topics in random order and the messages within each topic in random order.

02

Conditions studied

  • Alcohol Drinking

Browse trials for

03

In context

Alcohol Drinking

925 studies on the registry are indexed under Alcohol Drinking; 172 are open to participants now.

This study's enrollment of 2,522 is above the median of 108 across 802 interventional studies indexed under Alcohol Drinking.

Browse Alcohol Drinking studies →

Lead sponsor

Stanford University is the lead sponsor of 2,117 studies on the registry; 425 are open to participants now.

Of its 259 completed or terminated interventional studies of FDA-regulated products, 197 (76%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Age 21 and older
  • Reside in the United States
  • Able to complete a survey in English

Exclusion criteria

Exclusion Criteria:

  • Under 21 years of age
  • Reside outside the United States
  • Unable to complete a survey in English
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
2,522 participants (actual)

Study arms

  • Experimental
    Alcohol Messages

    Participants view 12 messages: 10 messages related to health topics (2 messages for each of 5 randomly selected health topics from among all health topics) and 2 control messages.

    Behavioral: Mouth cancer warning · Behavioral: Throat cancer warning · Behavioral: Voice box (larynx) warning · Behavioral: Esophagus cancer warning · Behavioral: Liver cancer warning · Behavioral: Colon and rectum cancer warning · Behavioral: Breast cancer · Behavioral: Cancer (generic, not site-specific) · Behavioral: Addiction and neurological changes · Behavioral: Hypertension · Behavioral: Liver damage · Behavioral: Harm to fetus · Behavioral: Dementia · Behavioral: Impaired sleep · Behavioral: Drinking guidelines · Behavioral: Control · Behavioral: Road injuries

Interventions

  • BehavioralMouth cancer warning

    Participants will view messages about the risk of mouth cancer from alcohol consumption.

  • BehavioralThroat cancer warning

    Participants will view messages about the risk of throat cancer from alcohol consumption.

  • BehavioralVoice box (larynx) warning

    Participants will view messages about the risk of voice box (larynx) cancer from alcohol consumption.

  • BehavioralEsophagus cancer warning

    Participants will view messages about the risk of esophagus cancer from alcohol consumption.

  • BehavioralLiver cancer warning

    Participants will view messages about the risk of liver cancer from alcohol consumption.

  • BehavioralColon and rectum cancer warning

    Participants will view messages about the risk of colon and rectum cancer from alcohol consumption.

  • BehavioralBreast cancer

    Participants will view messages about the risk of breast cancer from alcohol consumption.

  • BehavioralCancer (generic, not site-specific)

    Participants will view messages about the risk of cancer (not site-specific) from alcohol consumption.

  • BehavioralAddiction and neurological changes

    Participants will view messages about the risk of addiction and neurological changes from alcohol consumption.

  • BehavioralHypertension

    Participants will view messages about the risk of hypertension from alcohol consumption.

  • BehavioralLiver damage

    Participants will view messages about the risk of liver damage from alcohol consumption.

  • BehavioralHarm to fetus

    Participants will view messages about the risk of harm to a fetus from alcohol consumption during pregnancy.

  • BehavioralDementia

    Participants will view messages about the risk of dementia from alcohol consumption.

  • BehavioralImpaired sleep

    Participants will view messages about the risk of impaired sleep from alcohol consumption.

  • BehavioralDrinking guidelines

    Participants will view messages about guidelines for alcohol consumption.

  • BehavioralControl

    Participants will view neutral messages unrelated to the harms of alcohol consumption.

  • BehavioralRoad injuries

    Participants will view messages about the risk of road injuries from alcohol consumption.

06

What researchers measure

Primary outcomes

  1. Perceived message effectiveness

    The study will assess perceived message effectiveness using 1 item: "How much does this message discourage you from wanting to drink alcohol?" Response options will range from "not at all" (coded as 1) to "a great deal" (coded as 5). Higher scores indicate more perceived message effectiveness.

    Time frame: The survey will take up to 20 minutes.

Secondary outcomes

  1. Reactance

    The study will assess reactance using 1 item: "Say how much you disagree or agree with this statement: This message exaggerates the health effects of alcohol." Response options will range from "strongly disagree" (coded as 1) to "strongly agree" (coded as 5). Higher scores indicate more reactance.

    Time frame: The survey will take up to 20 minutes.

07

Study locations

1 site
  • Online study
    Palo Alto, California 94304, United States
08

References and documents

Study documents

  • Protocol and statistical analysis plan · Oct 3, 2023

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Yes — Investigators will post de-identified individual participant data in a publicly available repository.

Supporting information: Sap, Analytic code

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06159647
Lead sponsor
Stanford University
Responsible party
Anna Grummon (Assistant Professor, Stanford University) — Principal investigator
First posted
Dec 7, 2023
Start date
Jan 18, 2024
Primary completion
Jan 26, 2024
Completion
Jan 26, 2024
Last update
Feb 13, 2024

Study contacts

Anna Grummon, PhD
principal investigator · Assistant Professor

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion